Cargando…
Loading, please waitCargando…
Loading, please waitSourcing & Safety
Where the cells come from, who they came from, and how every batch is followed from donor to dose. A plain-language look at the donor screening, laboratory release testing, and chain-of-custody documentation that stand behind every infusion at Regeneris Therapy in Cancún, México.
At Regeneris Therapy in Cancún, México, every umbilical-cord MSC batch begins with a multi-step maternal donor screen — health and lifestyle history plus serology for HIV, hepatitis B and C, HTLV-I/II, syphilis, Chagas, CMV, and additional nucleic-acid testing. Each finished batch is released only after meeting the International Society for Cellular Therapy (ISCT) identity criteria (CD73 / CD90 / CD105 positive; CD45 / CD34 / HLA-DR negative; tri-lineage differentiation) plus sterility, mycoplasma and endotoxin testing. Every dose carries an ISBT-128-style unique batch identifier so the entire chain of custody — donor, processing lot, storage, transport, and patient — can be reconstructed on paper at any point.
Why sourcing is the decision
Patients are taught to compare 'protocols' and dose counts, but the variable that actually moves the safety needle in a stem-cell clinic in Cancún, México is upstream of any protocol: which donor, screened how, processed in which lab, released against which criteria, and labelled with what level of traceability. A perfect protocol applied to an under-screened or under-documented batch is not a safer therapy — it is a riskier one. The sections below describe exactly how Regeneris answers each link in that chain, in Cancún, México.
Donor screening, step by step
A simplified view of the gates a maternal cord donation passes through before any cells reach a Regeneris patient in Cancún, México. Each gate is documented; failing any single one disqualifies the unit from clinical use.
Before delivery, the prospective donor reviews a written informed-consent document and a structured questionnaire covering medical history, travel, lifestyle risk factors, and prior pregnancies — reviewed by a physician.
Maternal blood is tested for HIV-1/2, HBV (HBsAg and anti-HBc), HCV, HTLV-I/II, syphilis (RPR/T. pallidum), Chagas (T. cruzi), CMV, plus NAT for HIV, HBV and HCV — aligned with FDA 21 CFR 1271 donor-eligibility logic and international tissue-bank practice.
Cord tissue is collected only after term cesarean deliveries with no documented complication, with a sterile collection kit, and is delivered to the processing laboratory under cold-chain conditions logged at every handoff.
Identity, potency, sterility
Once a donation has cleared the screening gates and the MSCs have been expanded in a GMP-aligned laboratory, the finished batch is not handed to a physician on faith. It is released only after meeting a documented specification across four families of tests — identity, potency, safety, and dosing characteristics — the same logic regulatory authorities apply to advanced-therapy medicinal products (ATMPs). The list below summarises what is actually measured before a batch can be used on a patient in Cancún, México.
Chain of custody
Traceability is the link between a screened donor and a patient months later. Regeneris labels every clinical batch with a unique identifier styled on the ISBT 128 international coding standard — the same approach used by accredited stem-cell transplant programmes worldwide — so a single label can be used at any future date to reconstruct who the donor was, when the batch was processed, what release tests it passed, how it was stored, and which patient received which aliquot, in Cancún, México and beyond.
Each maternal cord donation enters the system with a pseudonymised donor identifier and a processing-lot identifier — permanently linked, never reissued, retained for the regulatory record-keeping window.
Every release test (identity, sterility, mycoplasma, endotoxin, viability) is recorded against the batch identifier with the date, the analyst's signature, and the specification each test was measured against.
Why this matters
Patients sometimes ask whether all of this is 'just paperwork'. It is not. The presence — or absence — of donor screening, release testing, and a documented chain of custody is the single largest driver of safety variance between regenerative clinics, and it shapes both the clinical experience and what is possible after the visit. The points below are practical, not abstract.
Donor screening with serology and nucleic-acid testing is the gate that catches transmissible-disease risk before any cells are cultured. It is the difference between a documented risk profile and an unknown one.
FAQ
The questions patients ask us most about cell sourcing, donor screening, and traceability — before they decide where to be treated in Cancún, México.
Our allogeneic umbilical-cord MSCs are sourced from Wharton's jelly collected ethically at term cesarean deliveries with documented written informed maternal consent — never from elective abortion. Each cord donation enters a documented chain of custody from the delivery room forward and is processed in a GMP-aligned laboratory. The maternal donor is screened by health history and serology before any cells from her donation can be released for clinical use in Cancún, México.
This page is informational and does not constitute medical advice. Stem cell therapy with umbilical-cord-tissue MSCs is investigational for many indications, and outcomes vary by patient, condition, and protocol. Donor screening, release testing, and chain-of-custody documentation reduce — but do not eliminate — biological risk. Any decision to undergo cellular therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals and any recent labs. One of our physicians in Cancún, México will review your case, explain exactly how the batch you would receive was sourced, screened, and released — and issue a personalized written quote after your free medical evaluation.
Donor screening is the first line of safety in regenerative medicine. Everything else — culture conditions, release testing, labelling — assumes that this gate was closed properly. We treat it that way.
The unit is processed and the resulting MSC bank is held in quarantine until every release test is signed off — donor serology, identity, sterility, mycoplasma, endotoxin, and viability — then released for clinical use against a documented specification.
The point of release testing is simple: a batch either meets specification on paper, or it does not leave the lab. There is no in-between. Your physician at Regeneris reviews these results before any infusion in Cancún, México.
Short, citation-ready definitions of the core terms on this page.
Cryogenic storage, retrieval, thawing, and transport to clinic each generate timestamped events against the batch identifier, with cold-chain temperatures logged continuously — interruptions are flagged before infusion.
At the moment of administration the batch identifier is recorded in the patient chart and on the take-home discharge documentation, so the same batch can be looked up later by patient, by physician, or by regulator.
If a regulator, a downstream physician, or a patient ever asks 'whose cells were these, and what was done to them', the answer is on paper — in Cancún, México and exportable on request.
ISCT identity testing answers 'are these cells what the label says they are?' before they are administered — preventing the well-documented problem of mislabelled or contaminated 'stem-cell' products in unregulated markets.
A traceable batch identifier means your home physician, your specialist, or a regulator can reconstruct exactly what was administered months or years later — turning a single visit into permanent medical evidence.
This is why Regeneris treats sourcing and traceability as the foundation of the protocol, not the small print after it.
Donor screening at Regeneris in Cancún, México combines a structured medical and lifestyle questionnaire reviewed by a physician with laboratory testing of maternal blood for HIV-1/2, hepatitis B (HBsAg and anti-HBc), hepatitis C, HTLV-I/II, syphilis, Chagas disease (T. cruzi), and CMV, plus nucleic-acid testing for HIV, HBV and HCV. The framework follows the donor-eligibility logic of FDA 21 CFR Part 1271, Subpart C — the international reference standard for human cells, tissues, and cellular and tissue-based products.
Release testing is the battery of laboratory tests a finished stem-cell batch must pass before it can leave the laboratory and be used on a patient. At Regeneris this means ISCT identity testing (CD73/CD90/CD105 positive; CD45/CD34/HLA-DR negative; tri-lineage differentiation), sterility testing for bacterial and fungal contamination, mycoplasma testing, endotoxin (LAL) testing, and viability — all against a written specification. A batch either meets specification on paper, or it does not leave the lab.
Every clinical batch carries a unique identifier styled on the ISBT 128 international coding standard used by accredited stem-cell programmes worldwide. That identifier links the pseudonymised donor, the processing lot, every release test, cold-chain storage and transport events, and the patient who ultimately received each aliquot. At the moment of infusion the batch identifier is recorded in the patient chart and on the take-home discharge documentation, so the chain of custody can be reconstructed later by a downstream physician or a regulator.
Patients receive a discharge document that records the unique batch identifier of the cells administered, the date of administration, the route, and the names of the physician and nurse involved. On request, your treating physician at Regeneris in Cancún, México can also provide a summary of the release-testing record for that batch, so your home physician can incorporate it into your permanent medical record after you travel back. We treat this paperwork as part of the therapy, not optional administration.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Why young, donor-screened cord-tissue cells are the leading allogeneic source for our regenerative protocols.